Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Symptoms and General Pathology

Infections

Heart and Blood Diseases

Rare Diseases

Prediabetic State

Kidney Diseases

Lung Diseases, Obstructive

Pulmonary Disease, Chronic Obstructive

COVID-19

Heart Failure

Atrial Fibrillation

Urolithiasis

Coronary Artery Disease

Myocardial Ischemia

Hypertension

Heart Diseases

Glucose Intolerance

Ischemia

Lung Diseases

Urinary Calculi

Albuminuria

Renal Insufficiency, Chronic

Renal Insufficiency

Coronary Disease

Vascular Diseases

Arrhythmias, Cardiac

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Respiratory Tract Diseases

Chronic Disease

Disease Attributes

Arteriosclerosis

Arterial Occlusive Diseases

Proteinuria

Urination Disorders

Urological Manifestations

Chronic Graft Versus Host Disease

Patients aged 40 or older without preexisting diagnoses of chronic kidney disease, type 1 diabetes, and type 2 diabetes with positive albuminuria by dipsticks and/or microalbuminuria test or albumin-to-creatinine ratio in a single urine sample.

Elena Semenova, PhD

Alexander Vaskin

Alexander Arutyunov, professor

Real clinical practice register of Albuminuria detection in patients with previously undiagnosed chronic kidney disease

This register was sponsored and organized by the Association "Eurasian Association of Internal Medicine". It is a multicenter non-interventional register of real clinical practice. The database will include patients aged 40 years and older without pre-existing nephrological disease who are available for a dipstick test for albuminuria. The subjects will be identified by screening all patients who meet inclusion/exclusion criteria during routine outpatient and hospital follow-up. The register does not include follow-up (cross-sectional design).

Patients eligible for the register should be enrolled and documented. The procedure for obtaining informed consent for the collection and analysis of the retrospective data must comply with the local legislation. If necessary, patients will be asked to sign an informed consent document.

All study sites will use standardized electronic CRFs. The Electronic Data Capture (EDC) system should be validated in accordance with current standards and legal requirements. The investigators will log into this system using individual usernames and passwords. Data may only be entered and corrected by the investigator or other authorized study site personnel.

Real Clinical Practice Register of AlbUminuRia Detection in Patients With Previously undiAgnosed Chronic Kidney Disease

Eurasian Association of Therapists

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

All Drugs and Chemicals

Antibodies

Immunoglobulins

Immunoglobulins, Intravenous

Immunologic Factors

This first phase aims to study the variations in urinary excretion of FLC immunoglobulin during the day and night to determine the appropriate time of day for collection of urine.

20 patients hospitalized.

Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row. This value will check the quality of urine collection for 24 hours during the study.

30 patients hospitalized.

First phase :

Collection of four urine samples daily for 2 days:

* Of the 24-hour urine
* at 8 AM
* at 12 AM
* at 4 PM

On each of these urine samples, the following analysis will be performed:

* Proteinuria
* Albuminuria
* Urinary FLC (Freelite ™)
* Urine creatinine

Second phase:

Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row.

urinary excretion of FLC immunoglobulin

Olivier DECAUX, MD

The measurement of 24-hour proteinuria allows an assessment of treatment response in patients with multiple myeloma. But it is difficult and restrictive to make.

This study was therefore designed to investigate the correlation between the ratio of proteinuria / creatinine on samples, easier to obtain, and the 24-hour proteinuria in assessing response to this treatment .

The measure of 24-hour proteinuria is an important biomarker for multiple myeloma.

Multiple myeloma is often accompanied by proteinuria overhead of secretion by plasma cells of large quantities of immunoglobulin free light chains (FLC) kappa or lambda. This proteinuria is composed of monoclonal FLC. The measure of the urinary concentration of FLC is an important biomarker for both diagnosis and evaluation of response to treatment of light chain multiple myeloma but also in intact immunoglobulins multiple myeloma.

The 24-hour proteinuria coupled with urine protein electrophoresis is the standard method for measuring the concentration of urinary FLC. However, it is difficult to obtain a reliable collection of the urine of 24 hours which can make it difficult to assess response to therapy in some patients. It would be interesting to assess proteinuria in a single urine sample collected at any time of day.

Contribution of urinary protein/creatinine ratio for assessment of proteinuria of glomerular origine.

For reasons of convenience, the extent of 24-hour proteinuria was increasingly abandoned by nephrologists in favor of urinary protein/creatinine ratio (UPCR). The use of UPCR measured on a sample of urine overcomes the inaccuracies related to the collection of 24 or variations in urine concentration. This report has been validated against the 24-hour proteinuria for screening or monitoring of renal glomerular diseases by the French Society of Nephrology. In theory, the UPCR is measured on a urine sample, taken preferably in the morning. In practice, the precision of a measurement at any time of day is quite acceptable.

Using the urinary protein/creatinine ratio for assessment of response in multiple myeloma?

The use of UPCR has been validated in patients with renal glomerular disease and especially in diabetic nephropathy. However, the UPCR has not been validated for the assessment of proteinuria overload such as those seen in myeloma. Two recent papers have studied the UPCR in multiple myeloma. The results of these articles suggest:

* That the UPCR is well correlated with the 24-hour proteinuria
* The UPCR varies over time depending on the response to treatment and could therefore be used to monitor patients on treatment

However, given their limits, these two articles do not alow to recommend the widespread use of UPCR instead of the classic 24-hour proteinuria in clinical practice yet. Prospective studies are needed to analyze the correlation between UPCR and proteinuria of 24 hours to assess response to therapy.

* Proteinuria
* Albuminuria
* Urinary FLC (Freelite ™)
* Urine creatinine

Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma

Correlation Between the Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma.

To study the correlation between the urinary protein/creatinine ratio in the sample and 24-hour proteinuria in the assessment of treatment response in patients with multiple myeloma.

To study the changes in urinary excretion of FLC during the day and night

Compare different methods for estimating the urinary concentration of FLC

Rennes University Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Real Clinical Practice Register of AlbUminuRia Detection in Patients With Previously undiAgnosed Chronic Kidney Disease	NCT05690009	Chronic Kidney ... Hypertension Chronic Heart F... Ischemic Heart ... Atrial Fibrilla... PreDiabetes Chronic Obstruc... Cancer Urolithiasis COVID-19		40 Years -	Eurasian Association of Therapists
Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma	NCT01572857	Multiple Myelom...	urinary excreti...	18 Years -	Rennes University Hospital

Spots Global Cancer Trial Database for albuminuria

Every month we try and update this database with for albuminuria cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for albuminuria

Every month we try and update this database with for albuminuria cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for albuminuria cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.